Not all generics firms are created equal.

David Wallace
Executive Editor
Generics Bulletin

AREA OF EXPERTISE

Generics, Biosimilars, and Value-Added Medicines

PUBLICATION

Generics Bulletin

YEARS OF INDUSTRY EXPERIENCE

BIO

Generics Bulletin's Executive Editor Dave Wallace has more than a decade of experience reporting on the global generics, biosimilars and value-added medicines industries. Bringing his education in law to bear on legislative and regulatory affairs, he also keeps a close eye on corporate strategy, personnel moves, and product pipelines.

Top Generics Companies In The Market

Generics Bulletin's annual Top 50 feature compiles a ranking of the off-patent industry's leading players. Ordering companies by size based on their generics, biosimilars and APIs business, the Generics Bulletin Top 50 provides a comprehensive rundown of the industry's most significant firms, offers insights into how their recent experiences have affected their standing among their peers and reveals how industry trends have shaped the competitive landscape over the past year.